Tagged: #pembrolizumab

17
Jul
2019

Australia's Therapeutic Goods Administration (TGA) has today given Keytruda® (pembrolizumab) provisional approval for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) bowel cancer.

Published in Latest News
Support Bowel Cancer Australia
Bowel Cancer Australia Social Media